دورية أكاديمية
Long-term efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in patients with type 1 diabetes
| العنوان: | Long-term efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in patients with type 1 diabetes |
|---|---|
| المؤلفون: | Gómez, Ana María |
| المساهمون: | Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Enfermedades Crónicas del Adulto |
| المصدر: | Diabetes Technology & Therapeutics; Vol. 19 Núm. 2 (2017) |
| سنة النشر: | 2017 |
| المجموعة: | Pontificia Universidad Javeriana: Repositorio Institucional PUJ |
| مصطلحات موضوعية: | Continuous glucose monitoring, Continuous subcutaneous insulin infusion, Hypoglycemia unawareness, Long-term follow-up, Low-glucose suspend function, Sensor augmented insulin pump therapy, Severe hypoglycemia, Type 1 diabetes |
| جغرافية الموضوع: | América del Sur, América Latina, Colombia, Bogotá (Colombia) |
| الوصف: | Q1 ; 109-114 ; Background: Literature supports short-term efficacy and safety of Sensor Augmented Insulin Pump (SAP) therapy in patients with type 1 diabetes (T1D). However, no data are available showing long-term outcomes. Our study describes the long-term outcomes of SAP therapy with low-glucose suspend feature (SAP+LGS) in hypoglycemia in a Colombian population with T1D and hypoglycemia. Methods: A cohort study was conducted with T1D patients receiving SAP+LGS therapy who initiated this therapy because of hypoglycemia at San Ignacio University Hospital diabetes center in Bogotá, Colombia. Glycated hemoglobin (A1c) was assessed at least every 6 months, severe hypoglycemia (SH) and hypoglycemia unawareness (HU) incidence yearly. Adherence to therapy was also evaluated. Results: One hundred eleven patients were included in the analysis. Total daily insulin dose was reduced during follow-up (mean difference −0.22 U/kg; 95% confidence interval [CI] −0.18 to −0.26; P < 0.001). A1c levels were reduced from a baseline value of 8.8% ± 1.9% to 7.5% ± 1.0% at 5 months (mean difference −1.3%; 95% CI −1.09 to −1.50; P < 0.001) and 7.1% ± 0.8% (mean difference −1.7%; 95% CI −1.59 to −1.90; P < 0.001) at the end of follow-up (47 months on average). The incidence of SH and HU episodes decreased significantly since the first year, and this effect was maintained over time (P < 0.001). Conclusions: SAP+LGS therapy in T1D patients with hypoglycemia led to a significant and sustained decrease in A1c during long periods of follow-up, as well as a significant reduction in SH and HU. Future randomized clinical trials are desired. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | PDF; application/pdf; Papel / Electrónico |
| اللغة: | Spanish; Castilian |
| العلاقة: | 1520-9156 / 1557-8593 (Electrónico); http://hdl.handle.net/10554/49416Test; https://doi.org/10.1089/dia.2016.0332Test |
| DOI: | 10.1089/dia.2016.0332 |
| الإتاحة: | https://doi.org/10.1089/dia.2016.0332Test http://hdl.handle.net/10554/49416Test |
| حقوق: | Atribución-NoComercial 4.0 Internacional ; http://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: | edsbas.5A2E731D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1089/dia.2016.0332 |
|---|